Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Orexo AB ( (SE:ORX) ) has provided an announcement.
Orexo AB has published its Annual Report 2025, outlining its strategic objectives, core capabilities, technology platforms, product pipeline, manufacturing strengths, and its position as a partner of choice in the pharmaceutical sector. The report, which also includes financial information, risk management, corporate governance details, and a separate sustainability report, provides stakeholders with a comprehensive view of the company’s operations, market positioning, and long-term value-creation efforts.
The documentation emphasizes Orexo’s innovation-focused approach rooted in science and proven market performance, highlighting areas such as markets served, technological innovation, and assembly tools for nasal devices. By consolidating governance, financials, and sustainability disclosures, Orexo aims to reinforce transparency, support investor assessment of risk and opportunity, and strengthen its competitive standing in the broader life sciences industry.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK21.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo AB is a science-driven pharmaceutical company that develops and commercializes medicines, with a focus on innovative drug delivery technologies such as nasal devices. The company operates in regulated healthcare markets and positions itself as a partner of choice in manufacturing, technology, and product development for targeted therapeutics.
Average Trading Volume: 55,843
Technical Sentiment Signal: Sell
Current Market Cap: SEK773.5M
Find detailed analytics on ORX stock on TipRanks’ Stock Analysis page.